PublishedMarch 31, 2022

Fintiv Analysis Proves That Fintiv Is Being Used To Leave Likely Invalid Patents In Force

A recently released study from Unified Patents has put numbers to the sense many patent attorneys already had—the Patent Trial and Appeal Board is spending a lot of time on Fintiv discretionary denial analysis.  And I’ll follow up on that in a future post.

But there’s one other thing that jumps out of the study’s data.

When the PTAB decides not to institute a decision on the merits, it spends an average of 25 pages on the decision.  In only 4% of these denials did the Board analyze Fintiv—typically to spend only a page to say that the PTAB doesn’t need to perform a Fintiv analysis because the petition does not present a reasonable likelihood of invalidity.

So we know the PTAB is doing its merits analysis first—just as you’d expect, given that the merits are the most important inquiry.

But if we look at procedural denials, the Board spends 20 pages on the decision.  And of those 20 pages, they devote 11 to Fintiv analysis—meaning that they’re spending about one-third as many pages on the merits in procedural denials (9) as they are in denials on the merits (24-25).  But we already know that the Board has to be looking at the merits first, and only then reaching Fintiv, because merits denials explicitly say that reaching Fintiv is unnecessary if the merits don’t support institution.  Beyond that, one of the Fintiv factors instructs the Board to examine the merits of the petition, another reason to expect them to perform merits analysis prior to Fintiv analysis.  

The expectation is that, in cases where the Board denies institution under Fintiv, the Board would present their merits discussion at equal length to that found in a merits-based decision on institution.  Only then would they find that, under Fintiv, the balance of factors means that a petition must be denied anyway, even if it appears to be a meritorious petition.  But instead, the Board appears to be giving short shrift to the merits in Fintiv denial cases, relying on Fintiv for the denial.

There’s really only one conclusion to draw from this.  When the Board denies institution based on Fintiv, they likely do so only when the merits are strong enough to render the patent likely invalid.  Otherwise, they would have denied the petition on the merits.

IPR was created to “screen[] out bad patents while bolstering valid ones.”  But Fintiv is being used to leave invalid patents in force—the exact opposite.

It’s time to get rid of Fintiv.

Josh Landau

Patent Counsel, CCIA

Joshua Landau is the Patent Counsel at the Computer & Communications Industry Association (CCIA), where he represents and advises the association regarding patent issues.  Mr. Landau joined CCIA from WilmerHale in 2017, where he represented clients in patent litigation, counseling, and prosecution, including trials in both district courts and before the PTAB.

Prior to his time at WilmerHale, Mr. Landau was a Legal Fellow on Senator Al Franken’s Judiciary staff, focusing on privacy and technology issues.  Mr. Landau received his J.D. from Georgetown University Law Center and his B.S.E.E. from the University of Michigan.  Before law school, he spent several years as an automotive engineer, during which time he co-invented technology leading to U.S. Patent No. 6,934,140.

Follow @PatentJosh on Twitter.

More Posts

The Ripple Effects of Patent Venue

A recent article described the outsized roles that two modest cities in Texas play in U.S. patent litigation, but there's more to the story of America’s odd patent venue rules. The article alludes t...

Another startup bites the dust, courtesy of patent trolls

A handful of interest groups like to claim that patent trolls are a myth—that they're a straw man used to shape IP policy in ways that are harmful to patent holders. Mycroft AI is one of many startu...

How Challenging Low Quality Patents is Lowering Drug Prices

The FTC made headlines in May when it announced it was challenging over 300 “junk” patents in the FDA’s “Orange Book,” including patents on popular drugs like Ozempic and Victoza. With this ...

Subscribe to Patent Progress

No spam. Unsubscribe anytime.